Cite
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.
MLA
van de Loosdrecht, Arjan A., et al. “A Novel Allogeneic Off-the-Shelf Dendritic Cell Vaccine for Post-Remission Treatment of Elderly Patients with Acute Myeloid Leukemia.” Cancer Immunology, Immunotherapy, vol. 67, no. 10, Oct. 2018, pp. 1505–18. EBSCOhost, https://doi.org/10.1007/s00262-018-2198-9.
APA
van de Loosdrecht, A. A., van Wetering, S., Santegoets, S. J. A. M., Singh, S. K., Eeltink, C. M., den Hartog, Y., Koppes, M., Kaspers, J., Ossenkoppele, G. J., Kruisbeek, A. M., & de Gruijl, T. D. (2018). A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunology, Immunotherapy, 67(10), 1505–1518. https://doi.org/10.1007/s00262-018-2198-9
Chicago
van de Loosdrecht, Arjan A., Sandra van Wetering, Saskia J. A. M. Santegoets, Satwinder Kaur Singh, Corien M. Eeltink, Yvonne den Hartog, Malika Koppes, et al. 2018. “A Novel Allogeneic Off-the-Shelf Dendritic Cell Vaccine for Post-Remission Treatment of Elderly Patients with Acute Myeloid Leukemia.” Cancer Immunology, Immunotherapy 67 (10): 1505–18. doi:10.1007/s00262-018-2198-9.